Skip to main content

Table 3 Results of meta-analysis for polymorphisms in different subgroups and cancer susceptibility

From: The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case–control studies

Comparison

Subgroup

Number

I2

PH

PZ

OR (95% CI)

G VS A

Ethnicity

     
 

 Arabian

3

84.9%

0.001

0.752

0.86 (0.33–2.23)

 

 Asian

14

64.8%

P < 0.001

0.255

1.05 (0.96–1.15)

 

 Caucasian

22

0.0%

0.661

0.502

1.01 (0.98–1.05)

 

 Mixed

1

NA

NA

0.940

0.99 (0.80–1.23)

 

Cancer type

     
 

 Ovarian cancer

4

0.0%

0.547

0.848

0.99 (0.90–1.09)

 

 Acute lymphoblastic leukemia

2

0.0%

0.887

0.979

1.00 (0.85–1.18)

 

 Breast cancer

13

58.6%

0.004

0.494

1.03 (0.95–1.10)

 

 Thyroid cancer

4

71.2%

0.015

0.043

1.27 (1.01–1.61)

 

 Bladder cancer

3

0.0%

0.921

0.815

0.98 (0.85–1.13)

 

 lung cancer

3

60.1%

0.082

0.166

0.88 (0.74–1.05)

 

 Others

11

0.0%

0.902

0.822

1.01 (0.91–1.08)

 

Method

     
 

 PCR–RFLP

12

22.3%

0.225

0.657

0.99 (0.93–1.05)

 

 Sequencing

2

0.0%

0.828

0.004

2.60 (1.37–4.94)

 

 TaqMan

13

0.0%

0.886

0.475

1.02 (0.97–1.07)

 

 PCR

4

82.4%

0.001

0.913

1.02 (0.78–1.33)

 

 ND

6

14.6%

0.321

0.663

1.01 (0.96–1.06)

 

 Others

3

68.3%

0.043

0.089

1.32 (0.96–1.82)

 

Source of control

     
 

 HB

23

66.0%

P < 0.001

0.445

1.03 (0.95–1.13)

 

 PB

12

0.0%

0.892

0.135

1.03 (0.99–1.08)

 

 Mixed

1

NA

NA

0.442

0.89 (0.67–1.19)

 

 Nested

4

0.0%

0.874

0.294

0.95 (0.86–1.05)

 

Sample size

     
 

  < 100

3

77.1%

0.013

0.419

1.54 (0.54–4.43)

 

  > 100

37

43.7%

0.003

0.424

1.02 (0.98–1.07)

 

Year

     
 

  ≤ 2010

20

0.0%

0.910

0.700

1.01 (0.97–1.04)

 

  > 2010

20

69.5%

0.000

0.272

1.06 (0.96–1.17)

GG + AG VS AA

Ethnicity

     
 

 Arabian

3

79.8%

0.007

0.739

1.21 (0.39–3.76)

 

 Asian

14

64.4%

P < 0.001

0.547

1.04 (0.91–1.20)

 

 Caucasian

24

0.6%

0.453

0.119

1.03 (0.99–1.08)

 

 Mixed

2

0.0%

0.620

0.765

1.03 (0.85–1.24)

 

Cancer type

     
 

 Ovarian cancer

4

0.0%

0.887

0.439

1.05 (0.93–1.17)

 

 Acute lymphoblastic leukemia

3

24.4%

0.267

0.397

0.90 (0.75–1.12)

 

 Breast cancer

13

47.0%

0.031

0.037

1.06 (0.98–1.15)

 

 Thyroid cancer

4

55.4%

0.081

0.033

1.36 (1.15–1.61)

 

 Bladder cancer

4

59.1%

0.062

0.370

0.89 (0.70–1.14)

 

 Lung cancer

3

51.2%

0.129

0.207

0.85 (0.66–1.09)

 

 Others

12

0.0%

0.910

0.597

1.03 (0.93–1.13)

 

Method

     
 

 PCR–RFLP

13

0.0%

0.965

0.840

1.01 (0.92–1.11)

 

 Sequencing

2

0.0%

0.956

0.001

4.00 (1.82–8.80)

 

 TaqMan

15

29.2%

0.137

0.269

1.04 (0.97–1.10)

 

 PCR

4

81.0%

0.001

0.862

1.03 (0.72–1.48)

 

 ND

6

28.0%

0.225

0.360

1.03 (0.97–1.09)

 

 Others

3

16.0%

0.304

0.051

1.45 (1.15–1.82)

 

Source of control

     
 

 HB

23

58.4%

P < 0.001

0.397

1.05 (0.94–1.18)

 

 PB

15

0.0%

0.656

0.015

1.06 (1.01–1.12)

 

 Mixed

1

NA

NA

0.461

0.88 (0.63–1.24)

 

 Nested

4

0.0%

0.979

0.190

0.92 (0.82–1.04)

 

Sample size

     
 

  < 100

3

65.8%

0.054

0.179

2.23 (0.69–7.21)

 

  > 100

40

32.9%

0.025

0.234

1.03 (0.98–1.09)

 

Year

     
 

  ≤ 2010

21

0.0%

0.815

0.166

1.03 (0.99–1.08)

 

  > 2010

22

62.0%

0.000

0.322

1.07 (0.94–1.22)

GG VS AA + AG

Ethnicity

     
 

 Arabian

3

73.9%

0.022

0.218

0.28 (0.04–2.13)

 

 Asian

14

52.7%

0.011

0.253

1.08 (0.95–1.23)

 

 Caucasian

22

0.0%

0.806

0.056

0.91 (0.82–1.00)

 

 Mixed

1

NA

NA

0.987

0.99 (0.44–2.23)

 

Cancer type

     
 

 Ovarian cancer

4

0.0%

0.678

0.014

0.69 (0.51–0.93)

 

 Acute lymphoblastic leukemia

2

0.0%

0.698

0.818

1.04 (0.75–1.45)

 

 Breast cancer

13

35.7%

0.097

0.101

0.92 (0.83–1.02)

 

 Thyroid cancer

4

29.8%

0.234

0.007

1.38 (1.09–1.75)

 

 Bladder cancer

3

52.3%

0.123

0.303

1.35 (0.76–2.37)

 

 Lung cancer

3

5.5%

0.347

0.062

0.83 (0.69–1.01)

 

 Others

11

0.0%

0.893

0.993

1.00 (0.88–1.13)

 

Method

     
 

 PCR–RFLP

12

18.3%

0.265

0.421

0.96 (0.86–1.06)

 

 Sequencing

2

0.0%

0.818

0.621

1.63 (0.23–11.46)

 

 TaqMan

13

41.3%

0.059

0.462

0.95 (0.84–1.08)

 

 PCR

4

44.2%

0.146

0.211

0.88 (0.71–1.08)

 

 ND

6

8.8%

0.360

0.363

0.94 (0.81–1.08)

 

 Others

3

60.9%

0.078

0.121

1.54 (0.89–2.64)

 

Source of control

     
 

 HB

23

55.0%

0.010

0.614

1.04 (0.90–1.20)

 

 PB

12

0.0%

0.862

0.111

0.91 (0.81–1.02)

 

 Mixed

1

NA

NA

0.674

0.84 (0.38–1.02)

 

 Nested

4

0.0%

0.536

0.967

1.00 (0.80–1.24)

 

Sample size

     
 

  < 100

3

0.0%

0.537

0.339

0.64 (0.26–1.59)

 

  > 100

37

36.9%

0.014

0.766

0.99 (0.90–1.07)

 

Year

     
 

  ≤ 2010

20

0.0%

0.928

0.068

0.94 (0.83–1.01)

 

  > 2010

20

58.0%

0.001

0.374

1.08 (0.92–1.27)

GG VS AA

Ethnicity

     
 

 Arabian

3

75.4%

0.017

0.338

0.33 (0.04–3.15)

 

 Asian

14

47.8%

0.024

0.279

1.08 (0.93–1.26)

 

 Caucasian

22

0.0%

0.812

0.083

0.91 (0.82–1.01)

 

 Mixed

1

NA

NA

0.981

0.99 (0.44–2.23)

 

Cancer type

     
 

 Ovarian cancer

4

0.0%

0.705

0.028

0.71 (0.53–0.96)

 

 Acute lymphoblastic leukemia

2

0.0%

0.836

0.961

0.99 (0.67–1.47)

 

 Breast cancer

13

37.7%

0.082

0.311

0.94 (0.85–1.05)

 

 Thyroid cancer

4

45.7%

0.137

0.001

1.50 (1.17–1.93)

 

 Bladder cancer

3

0.0%

0.860

0.773

1.06 (0.72–1.55)

 

 Lung cancer

3

53.1%

0.119

0.019

0.79 (0.56–1.11)

 

 Others

11

0.0%

0.884

0.798

1.02 (0.88–1.19)

 

Method

     
 

 PCR–RFLP

12

10.7%

0.340

0.591

0.96 (0.85–1.10)

 

 Sequencing

2

0.0%

0.837

0.264

3.09 (0.43–22.45)

 

 TaqMan

13

0.0%

0.701

0.297

0.93 (0.81–1.07)

 

 PCR

4

73.8%

0.010

0.937

0.98 (0.61–1.58)

 

 ND

6

2.7%

0.399

0.436

0.94 (0.82–1.09)

 

 Others

3

0.0%

0.409

P < 0.001

1.97 (1.36–2.87)

 

Source of control

     
 

 HB

23

52.8%

0.002

0.628

1.04 (0.88–1.24)

 

 PB

12

0.0%

0.911

0.185

0.92 (0.82–1.04)

 

 Mixed

1

NA

NA

0.604

0.81 (0.36–1.80)

 

 Nested

4

0.0%

0.553

0.737

0.96 (0.76–1.21)

 

Sample size

     
 

  < 100

3

18.0%

0.295

0.796

0.87 (0.31–2.48)

 

  > 100

37

32.5

0.031

0.733

0.98 (0.89–1.08)

 

Year

     
 

  ≤ 2010

20

0.0%

0.961

0.070

0.91 (0.82–1.01)

 

  > 2010

20

55.2%

0.002

0.356

1.06 (0.96–1.17)

AG VS AA

Ethnicity

     
 

 Arabian

3

54.9%

0.109

0.174

1.76 (0.78–3.95)

 

 Asian

14

65.7%

P < 0.001

0.906

1.01 (0.86–1.18)

 

 Caucasian

22

0.0%

0.631

0.023

1.05 (1.01–1.10)

 

 Mixed

1

NA

NA

0.937

0.99 (0.77–1.27)

 

Cancer type

     
 

 Ovarian cancer

4

0.0%

0.998

0.145

1.09 (0.97–1.22)

 

 Acute lymphoblastic leukemia

2

0.0%

0.747

0.893

0.98 (0.78–1.24)

 

 Breast cancer

13

42.3%

0.054

0.006

1.08 (1.02–1.13)

 

 Thyroid cancer

4

33.2%

0.213

0.012

1.27 (1.05–1.53)

 

 Bladder cancer

3

87.1%

P < 0.001

0.038

0.71 (0.41–1.23)

 

 Lung cancer

3

26.7%

0.255

0.132

0.87 (0.73–1.04)

 

 Others

11

0.0%

0.935

0.710

1.02 (0.92–1.13)

 

Method

     
 

 PCR–RFLP

12

0.0%

0.981

0.590

1.03 (0.93–1.14)

 

 Sequencing

2

0.0%

0.946

0.001

4.00 (1.79–8.94)

 

 TaqMan

13

57.1%

0.006

0.696

1.02 (0.92–1.14)

 

 PCR

4

72.9%

0.011

0.780

1.05 (0.76–1.44)

 

 ND

6

35.1%

0.173

0.205

1.04 (0.98–1.11)

 

 Others

3

0.0%

0.577

0.089

1.25 (0.97–1.63)

 

Source of control

     
 

 HB

23

56.0%

0.001

0.421

1.05 (0.93–1.18)

 

 pb

12

0.0%

0.803

0.002

1.09 (1.03–1.15)

 

 MIXED

1

NA

NA

0.518

0.89 (0.62–1.27)

 

 Nested

4

0.0%

0.989

0.160

0.91 (0.80–1.04)

 

Sample size

     
 

  < 100

3

31.6%

0.232

0.003

2.82 (1.42–5.57)

 

  > 100

37

32.9%

0.029

0.153

1.04 (0.99–1.10)

 

Year

     
 

  ≤ 2010

20

0.0%

0.667

0.047

1.05 (1.00–1.10)

 

  > 2010

20

60.8%

0.000

0.278

1.08 (0.94–1.25)

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us